Alto Neuroscience, Inc. (ANRO)
NYSE: ANRO · Real-Time Price · USD
14.04
+0.42 (3.08%)
At close: Oct 29, 2025, 4:00 PM EDT
13.81
-0.23 (-1.64%)
After-hours: Oct 29, 2025, 4:49 PM EDT
Alto Neuroscience Employees
Alto Neuroscience had 76 employees as of December 31, 2024.
Employees
76
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$853,408
Market Cap
380.16M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 76 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ANRO News
- 1 day ago - Alto Neuroscience to Participate in Upcoming Investor Conferences - Business Wire
- 9 days ago - Alto Neuroscience Announces $50 Million Private Placement Financing - Business Wire
- 9 days ago - Alto Neuroscience Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting - Business Wire
- 21 days ago - Johnson Fistel, PLLP Investigates Claims on Behalf of Alto Neuroscience, Inc. Long-Term Shareholders - GlobeNewsWire
- 26 days ago - Johnson Fistel, PLLP Investigates Claims on Behalf of Alto Neuroscience, Inc. Long-Term Shareholders - GlobeNewsWire
- 26 days ago - Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia - Business Wire
- 6 weeks ago - INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience - PRNewsWire
- 7 weeks ago - Alto Neuroscience Announces Robust Replication of EEG Biomarker to Objectively Identify Patients with Cognitive Impairment in Schizophrenia - Business Wire